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Abstract The FRAX tool has been used to determine
possible thresholds for therapeutic intervention; however,
there are no FRAX-based intervention thresholds available
for China, we proposed that the 10-year probability of
major osteoporotic fracture and hip fracture of about 4.0
and 1.3 %, respectively, may be acceptable intervention
thresholds for central south Chinese postmenopausal
women.
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Introduction
In recent years, the World Health Organization (WHO) has
developed a fracture risk assessment tool termed FRAX.
Using easily obtainable clinical risk factors, with or with-
out femoral neck bone mineral density (BMD), FRAX
provides models for assessing the 10-year probability of a
major osteoporotic fracture and a hip fracture, and deter-
mines possible thresholds for therapeutic intervention.
However, the WHO makes no specific recommendation
concerning intervention thresholds, because these depend
on many local factors [1]. WHO suggests that each country
should determine their own intervention thresholds, based
on the local healthcare situation and the cost-effectiveness
of the treatment of osteoporosis.
Clinical guidelines on when to intervene, based on
fracture probability, have been developed for Europe,
Canada, Germany, Japan, the UK, and the US [2–7]. Two
approaches have been developed for guidelines based on
fracture probability [8]. The first is to ‘‘translate’’ current
practice in the light of FRAX; the UK guidance for the
management of men and women at high fracture risk
developed by the National Osteoporosis Guideline Group
(NOGG) is an example of the translation of existing
guidance provided by the Royal College of Physicians
(RCP) [9–11] into probability-based assessment [2]. The
RCP guidance indicates that treatment should be recom-
mended for women with a prior fragility fracture, without
the need for measuring BMD, an approach that has been
shown to be cost-effective in women aged[50 years [12].
For this reason, the intervention threshold set by NOGG
was at the fracture probability equivalent of women with a
prior fragility fracture without BMD testing [2]. The sec-
ond approach is the determination of the threshold of
fracture probability at which intervention becomes cost-
effective. The preferred method is cost–utility analysis,
which integrates the number of deaths and disability
avoided with the multiple outcomes by measuring quality-
adjusted life-years (QALYs) [8]. The health-economic
thresholds of £30,000 and £20,000 per QALY gained in the
UK [13–15], or $60,000 per QALY gained in the US [16],
have been used to determine cost-effectiveness. For
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example, the National Osteoporosis Foundation updated its
pre-existing clinical practice guidelines [17] with a health-
economic analysis [16]. The threshold for cost-effective-
ness was set at $60,000 per QALY gained in both men and
women; treatment became cost-effective at a hip fracture
probability of approximately 3 %, which was chosen as the
intervention threshold.
At present, although fracture probabilities derived from
FRAX can be computed in some Asian countries; how-
ever, there are no specific FRAX-based intervention
thresholds available in China. Hong Kong is developing
the translational approach to guidelines [14], and the
selection of individuals at high risk for treatment in Sri
Lankan postmenopausal women is being carried out
according to the US Caucasian tool [18]. In Japan, Fu-
jiwara [4] proposed that a 10-year probability of 10 % for
osteoporosis-related fracture might be an acceptable
intervention threshold. However, it is not suitable to use
other countries’ thresholds as a surrogate threshold for
China. In a prospective study, the predicted 10-year risk of
osteoporotic fracture in Hong Kong Southern Chinese
women was substantially higher than that for mainland
Chinese women [19]. Kwok [20] found that the preva-
lence of vertebral fracture was higher in Japan compared
with Hong Kong, Thailand, and Indonesia. When the
10-year risk of hip fracture in women with a BMI of
24 kg/m2 aged 40, 50, 60, 70, 80, and 90 years with no
other clinical risk factors was estimated, the predicted
fracture probability in Chinese mainland women was
much lower than that in the UK or Chinese Hong Kong,
as shown in Fig 1. Moreover, as there is little information
on the epidemiology of fracture and death, and systematic
drug economics research in China, we cannot determine
the intervention thresholds according to the above
approaches. For this reason, we want to discuss the
interventional thresholds based on FRAX in central
Southern China.
We attempted to set intervention thresholds based on the
10-year probability of major osteoporotic fracture and hip
fracture calculated with BMD. In our previous study of 778
urban postmenopausal women [21], there were 292
(37.5 %) women with osteoporosis; the osteoporotic
women were aged from 51 to 71 years. The 62.5th per-
centiles of major osteoporotic fracture and hip fracture
probability calculated with BMD for the 778 subjects were
4.0 and 1.3 %, respectively. Correspondingly there were
37.5 % subjects who had a 10-year probability of major
osteoporotic fracture and hip fracture that exceeded 4.0 and
1.3 %, respectively, and this percentage corresponded to
the proportion of subjects with osteoporosis. As FRAX can
be used without BMD values, it will provide an interim
solution to the limitation in the central-type DXA facility
currently observed in China. Thus, we propose that, inter-
vention for both BMD testing and treatment would be
recommended for individuals with a 10-year probability of
major osteoporotic fracture that exceeded 4.0 % or a
10-year probability of hip fracture that exceeded 1.3 %.
However, clinical judgment needs to be used, because the
cost-effectiveness of therapeutic intervention could vary
depending on the specific drug used, and may avoid costly
and potentially unnecessary treatment. In summary, we
present a hypothesis that the 10-year probabilities of major
osteoporotic fracture and hip fracture of about 4.0 and
1.3 %, respectively, may be currently acceptable as the
Fig. 1 Comparison of 10-year
probability of hip fracture in
different FRAX models, BMI is
set at 24 kg/m2
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intervention thresholds for central Southern Chinese post-
menopausal women; however, the decision to intervene
should take account of health and economic consequences
for individuals and for the health care budget. It is note-
worthy that China is a large country with a heterogeneous
population, while only a small sample size was included in
our analysis; therefore, our conclusion will require further
confirmation. However, it may serve to suggest FRAX-
based intervention thresholds in the Chinese setting. The
adoption of FRAX-based intervention thresholds will
demand a reappraisal of the criteria for reimbursement of
interventions and health-economic assessments.
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